Autobahn Therapeutics, Inc.

Market position

Autobahn is a private clinical-stage CNS biotechnology company. One data provider ranks it among the largest San Diego biotechnology companies by reported capital raised (ahead of roughly 90% of tracked sector peers), while noting its latest reported round is below the median for its modeled stage cohort. Listed similar companies include BlackThorn Therapeutics, Alto Neuroscience and Neurana Pharmaceuticals.

The company positions its brain-targeting prodrug chemistry as enabling bespoke central versus peripheral exposure ratios, addressing the historical limitation of thyroid hormone approaches in psychiatry — peripheral thyroid effects. Management and an external clinician cited in the June 2026 release describe the AMPLIFY-BD results as the first clinical evidence for CNS-targeted thyroid hormone receptor agonism, a mechanism intended to enhance brain energy metabolism and neuroplasticity, with claimed differentiation on rapid onset, depth and durability of response, and tolerability.

Technology

A brain-targeting chemistry platform generating orally administered small molecule prodrugs with tunable central-versus-peripheral exposure ratios. Lead compound elunetirom (ABX-002) is an oral, once-daily, brain-penetrant thyroid hormone receptor (TRβ) agonist intended to enhance brain energy metabolism and neuroplasticity; ABX-101 is described as a next-generation CNS-active S1P program. Development uses biomarkers and neuroimaging, including resting-state functional MRI, to assess proof-of-mechanism.

Go-to-market

As a clinical-stage developer, the company's external activity centers on clinical trial execution, regulatory engagement (planned FDA interactions to assess a registration path in bipolar depression following Fast Track designation), and scientific presentations at industry meetings such as ASCP and ACNP, as well as investor conferences including Evercore's Emerging Private Biotech Conference.

Patients with rare and prevalent CNS disorders, with current clinical programs addressing adults with bipolar I/II depression (a population the company cites as approximately 7 million U.S. adults) and major depressive disorder; prescribers are psychiatrists and other clinicians treating mood disorders.

Geography

Headquartered in San Diego, California (9880 Campus Point Drive, San Diego, CA 92121). One directory reports employees across North America and Oceania.

History

The company was founded in 2017 and is based in San Diego, California, at 9880 Campus Point Drive. A financing was reported in July 2024 ($100M per one report; $200M Series C per another aggregator; $100.8M offering with a first sale date of 2024-06-20 in a Form D-derived record). Phase 1 results for ABX-002 were presented at the 2025 ASCP Annual Meeting, and preclinical data were presented at the ACNP Annual Meeting in January 2026 and the ASCP Annual Meeting in May 2026. Elunetirom received FDA Fast Track designation for adjunctive treatment of bipolar depression in May 2026, followed by positive Phase 2 AMPLIFY-BD topline data announced on June 4, 2026.

Risks & controversies

Sources report conflicting funding figures for the 2024 financing ($100M, $200M Series C, and a $100.8M reported offering) and differing totals to date ($209M per one directory). The AMPLIFY-BD Phase 2 trial was open-label and small (21 patients), with no control arm described. The lead program remains in Phase 2 with the MDD readout still pending, and one analytics provider notes the company had not raised for about two years against a sector cadence of roughly 14 months.